Research programme: diabetes/obesity therapy - Serono Genetics Institute

Drug Profile

Research programme: diabetes/obesity therapy - Serono Genetics Institute

Alternative Names: Famoxin; gAPM1

Latest Information Update: 28 Nov 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator INSERM; Serono Genetics Institute
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 25 Oct 2002 Genset has been acquired by Serono
  • 20 May 2002 Genset has selected Eurogentec to manufacture Famoxin
  • 08 Aug 2001 Genset has announced the production of the human protein fragment
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top